Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

Investing.com -- DexCom (NASDAQ:DXCM) stock fell 3% Thursday after Hunterbrook Media published a scathing short report alleging serious safety issues with the company’s G7 continuous glucose ...

Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. DexCom, Inc. is one of them.

With significant upside potential, DexCom, Inc. (NASDAQ:DXCM) secures a spot on our list of the 13 Best Quality Stocks to Buy According to Hedge Funds. On September 25, 2025, given that previous ...

Shares of DexCom (DXCM) declined 10% on Friday after investment firm Hunterbrook Capital disclosed a short position in the stock. Hunterbrook said on Thursday that it has a short position on DXCM ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...